straightforward way. And it was really important to me that it was honest. I didn't feel like they kept their concern from me. At the same time, they were focused on "so here's what we're going to do." And that gave me a sense of purpose and sort of the ability to focus on...
either [through] a clinical trial or with [adjuvant] capecitabine [based on] the CREATE-X data. In the metastatic setting, the current standard of care is still sequential single-agent chemotherapy; however, ADCs such as sacituzumab govitecan...
Adam M. Brufsky, MD, PhD:So, there are 2 randomized trials that we have. There’s OlympiAD and there’s EMBRACA. They both, basically, are very similar both in their design and their outcome. In OlympiAD, I think it was about 300 women, 302 women, with germlineBRCA-associated breast ...
cancer itself, that may be what makes it uniquely sensitive. We know some of those tumors are basal-like. If you look at the non-HER2 enriched tumors, that may be another group that is resistant with a lot of host immune response where there can be a unique response to checkpoint ...
Rugo mentioned that she generally does not use combination chemotherapy in a patient case like this, but when she does decide on using combination chemotherapy in the frontline setting, it would be with gemcitabine and carboplatin. Although chemotherapy, and particularly combination therapy, is still ...
Aditya Bardia, MD, MPH, discusses how the antibody-drug conjugate sacituzumab govitecan-hziy can address the unmet need in metastatic triple-negative breast cancer and the toxicities seen with the therapy.
Aditya Bardia, MD, MPH:And I would build up on this. I agree. I think there is definitely excitement about immunotherapy and it works for a subset of patients. The challenge is I didn’t find that subset, and the interest. The first step is obviously to look at PD-1, but that migh...
Although sacituzumab is looking like it’s superior, I don’t know that we could say much about the TPC arms in a head-tohead comparison here. I think this all looks pretty consistent with what physician practice would be in the drugs that we choose.3 How does germline BRCA status ...
Claudine Isaacs, MD:I would echo what has been said. Obviously, we’re looking at immunotherapy as well, and we’ll get to that in a few moments. Just to go back to Hope’s presentation from the CALGB trial, you know, overall, we remember that trial. It was trying to look at ixab...